[1] Boucher HW, Talbot GH, Bradley JS, et al.Bad bugs, no drugs:no ESKAPE! an update from the infectious diseases society of america[J]. Clin Infect Dis, 2009, 48(1):1-12. [2] Gilbert DN, Guidos RJ, et al.The 10 X’20 initiative:pursuing a global commitment to develop 10 new antibacterial drugs by 2020[J]. Clin Infect Dis, 2010, 50(8):1081-1083. [3] 刘志恒. 放线菌-微生物药物的重要资源[J]. 微生物学通报, 2005, 32(6):143-145. [4] Goodfellow M, Williams ST.Ecology of actinomycetes[J]. Annu Rev Microbiol, 1983, 37:189-216. [5] Katsifas EA, Giannoutsou EP, Karagouni AD.Diversity of streptomycetes among specific Greek terrestrial ecosystems[J]. Lett Appl Microbial, 1999, 29(1):48-51. [6] Alvan G, Edlund C, Heddini A.The global need for effective antibiotics—A summary of plenary presentations[J]. Drug Resis Updat, 2011, 14:70-76. [7] Zotchev SB.Marine actinomycetes as an emerging resource for the drug development pipelines[J]. J Biotechnol, 2012, 158:168-175. [8] Lazzarini A, Cavaletti L, Toppo G, et al.Rare genera of actinomyc-etes as potential producers of new antibiotics[J]. Anton Leeuw, 2000, 78:399-405. [9] Clardy J, Fischbach MA, Currie CR.The natural history of antibiotics[J]. Curr Biol, 2009, 19(11):R437-R441. [10] Tortorella E, Tedesco P, Esposito FP, et al.Antibiotics from deep-sea microorganisms:current discoveries and perspectives[J]. Mar Drugs, 2018, 16(10):355. [11] Qin S, Li WJ, Klenk HP, et al.Editorial:Actinobacteria in special and extreme habitats:Diversity, function roles and environmental adaptations, second edition[J]. Front Microbiol, 2019, 10:944. [12] Carro L, Casteo JF, Razmilic V, et al.Uncovering the potential of novel micromonosporae isolated from an extreme hyper-arid Atacama Desert Soil[J]. Sci Rep, 2019, 9:4678. [13] Shirling EB, Gottlieb D.Methods for characterization of Streptomyces species[J]. Int J Syst Bacteriol, 1966, 16(3):313-340. [14] Singh LS, Sharma H, Talukdar NC.Production of potent antimicrobial agent by actinomycete, Streptomyces sannanensis strain SU118 isolated from phoomdi in Loktak Lake of Manipur, India[J]. BMC Microbiol, 2014, 14:278. [15] 程丽娟, 薛泉宏, 米航线, 等. 微生物学实验技术[M]. 西安:世界图书出版公司, 1988. [16] Kirienko NV, Cezairliyan BO, Ausubel FM, et al.Pseudomonas aeruginosa PA14 Pathogenesis in Caenorhabditis elegans[J]. Methods Mol Biol, 2014, 1149:653-669. [17] Tamura K, Stecher G, Peterson D, et al.MEGA6:molecular evolutionary genetics analysis version 6. 0[J]. Mol Biol Evol, 2013, 30(12):2725-2729. [18] Brenner S.The genetics of Caenorhabditis elegans[J]. Genetics, 1974, 77:71-94. [19] Moy TI, Ball AR, Ausubel FM, et al.Identification of novel antimicrobials using a live-animal infection model[J]. Proc Natl Acad Sci USA, 2006, 103(27):10414-10419. [20] Kim M, Oh HS, Park SC, et al.Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes[J]. Int J Syst Evol Micr, 2014, 64(2):346-351. [21] 罗红丽, 黄英, 王黎明, 等. 西藏地区土壤放线菌种群多样性及拮抗活性研究[J]. 微生物学报, 2005(5):724-727. [22] 夏占峰, 关统伟, 阮继生, 等. 艾丁湖沉积物放线菌多样性[J]. 微生物学报, 2011, 51(8):1023-1031. [23] 张学武. 小单孢菌属的分类及应用研究[J]. 微生物学通报, 2006, 33(5):117-121. [24] Zothanpuia, Passari AK, Leo VV, et al. Bioprospection of actinobacteria derived from freshwater sediments for their potential to produce antimicrobial compounds[J]. Microb Cell Fact, 2018, 17(1):68. [25] Kumar RR, et al.Isolation of actinomycetes:A complete approach[J]. Int J Curr Microbiol Appl Sci, 2016, 5(5):606-618. [26] 杨再昌, 杨小生. 秀丽隐杆线虫(Caenorhabditis elegans)在药物筛选中的应用[J]. 生命科学, 2009, 21(4):593-598. [27] Breger J, Fuchs BB, Aperis G, et al.Antifungal chemical compounds identified using a C. elegans pathogenicity assay[J]. PLoS Pathog, 2007, 3(2):e18. [28] 史秋佳, 杨剑萍, 陈缵光. 秀丽隐杆线虫作为抗感染药物筛选模型的研究进展[J]. 中国药理学通报, 2013, 29(10):1333-1336. [29] Balla KM, Troemel ER.Caenorhabditis elegans as a model for intracellular pathogen infection[J]. Cell Microbiol, 2013, 15(8):1313-1322. |